Reason for request
Taking account of these points, the Committee considers that the actual benefit of STABLON remains substantial in major depressive episodes (i.e. typical).
The Committee recommends continued inclusion on the list of medicines refundable by National Health Insurance and on the list of proprietary products approved for hospital use in the indication “ major depressive episodes (i.e. typical) ” and at the dosages in the Marketing Authorisation.